SLC38A9: A Potential Drug Target Or Biomarker for Diabetes, Cancer and Neurodegenerative Disorders

Target Name: SLC38A9

NCBI ID: G153129

SLC38A9

SLC38A9: A Potential Drug Target Or Biomarker for Diabetes, Cancer and Neurodegenerative Disorders

SLC38A9 (SLC38A9 variant 1) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and heart. It is a member of the solute carrier family 38 (SLC38) and is involved in the transport of various molecules across cell membranes. SLC38A9 has been identified as a potential drug target or biomarker for several diseases, including diabetes, cancer, and neurodegenerative disorders.

SLC38A9 is a 21-kDa protein that is expressed in the brain, pancreas, and heart. It is a member of the solute carrier family 38 (SLC38) and is involved in the transport of various molecules across cell membranes. SLC38A9 has been identified as a potential drug target or biomarker for several diseases, including diabetes, cancer, and neurodegenerative disorders.

One of the key functions of SLC38A9 is its role in the transport of glucose across the blood-brain barrier (BBB). The BBB is a specialized barrier that separates the brain from the blood and is designed to protect it from harmful substances. However, glucose, which is essential for brain function, can also be harmful if it crosses the BBB too quickly. SLC38A9 is involved in regulating the rate at which glucose enters the brain, which is critical for maintaining proper brain function.

SLC38A9 has also been shown to be involved in the transport of other molecules across cell membranes. For example, SLC38A9 has been shown to be involved in the transport of amino acids, such as glutamate and aspartate, which are important for neurotransmitter synthesis and release. It has also been shown to be involved in the transport of nucleotides, which are the building blocks of DNA and RNA, which are important for cellular signaling.

In addition to its role in cell signaling, SLC38A9 has also been shown to be involved in the regulation of cellular processes that are important for overall health. For example, SLC38A9 has been shown to be involved in the regulation of inflammation, which is important for fighting off harmful bacteria and viruses that can cause a variety of diseases. It has also been shown to be involved in the regulation of cell division, which is important for the growth and development of tissues.

SLC38A9 has been identified as a potential drug target or biomarker for several diseases, including diabetes, cancer, and neurodegenerative disorders. For example, SLC38A9 has been shown to be overexpressed in pancreatic cancer, which is a common cause of cancer-related deaths. It has also been shown to be involved in the regulation of insulin sensitivity, which is important for the treatment of type 2 diabetes.

In addition to its potential clinical applications, SLC38A9 has also been shown to be a promising biomarker for several diseases. For example, SLC38A9 has been shown to be elevated in the blood of individuals with Alzheimer's disease, which is a common cause of dementia. It has also been shown to be elevated in the blood of individuals with depression, which is a common mental disorder.

In conclusion, SLC38A9 is a protein that is expressed in various tissues throughout the body and is involved in the transport of various molecules across cell membranes. SLC38A9 has been identified as a potential drug target or biomarker for several diseases, including diabetes, cancer, and neurodegenerative disorders. Further research is needed to fully understand the role of SLC38A9 in cellular processes and to develop effective treatments for these diseases.

Protein Name: Solute Carrier Family 38 Member 9

Functions: Lysosomal amino acid transporter involved in the activation of mTORC1 in response to amino acid levels (PubMed:25567906, PubMed:25561175, PubMed:29053970). Probably acts as an amino acid sensor of the Rag GTPases and Ragulator complexes, 2 complexes involved in amino acid sensing and activation of mTORC1, a signaling complex promoting cell growth in response to growth factors, energy levels, and amino acids (PubMed:25567906, PubMed:29053970). Following activation by amino acids, the Ragulator and Rag GTPases function as a scaffold recruiting mTORC1 to lysosomes where it is in turn activated (PubMed:25567906, PubMed:25561175). SLC38A9 mediates transport of amino acids with low capacity and specificity with a slight preference for polar amino acids (PubMed:25561175, PubMed:25567906). Acts as an arginine sensor (PubMed:25567906, PubMed:29053970, PubMed:31295473). Following activation by arginine binding, mediates transport of L-glutamine, leucine and tyrosine with high efficiency, and is required for the efficient utilization of these amino acids after lysosomal protein degradation (PubMed:29053970) (Probable). However, the transport mechanism is not well defined and the role of sodium is not clear (PubMed:25561175, PubMed:31295473). Can disassemble the lysosomal folliculin complex (LFC), and thereby triggers GAP activity of FLCN:FNIP2 toward RRAGC (PubMed:32868926). Acts as an cholesterol sensor that conveys increases in lysosomal cholesterol, leading to lysosomal recruitment and activation of mTORC1 via the Rag GTPases (PubMed:28336668). Guanine exchange factor (GEF) that, upon arginine binding, stimulates GDP release from RRAGA and therefore activates the Rag GTPase heterodimer and the mTORC1 pathway in response to nutrient sufficiency (PubMed:30181260)

The "SLC38A9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC38A9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets